How can AID systems like Omnipod 5 ease the mental burden on patients living with diabetes? To find out, Beyond the Bolus hosts Nancy Hanna and Dena Gottesman handed over hosting duties to our international colleague, Kate Neal, who was at ATTD in Amsterdam speaking with Dr. Eden Miller, a family practitioner, diabetologist, and co-founder of Diabetes Nation.

Dr. Miller shares her perspective (as both a healthcare provider and a person living with diabetes), explaining why she considers Omnipod 5 to be a “diabetes partner” – one that adapts and helps patients live more freely with less mental burden. They discuss how customizable glucose targets, setting adjustments, and the Custom Foods feature provide patients with a personalized and supportive experience.

Kate and Dr. Miller take a closer look at the SECURE-T2D study, which evaluated the use of Omnipod 5 in adults with type 2 diabetes. Dr. Miller outlines the key results and reflects on how the findings are already transforming her clinical practice.

You’ll also hear stories from Dr. Miller’s practice, such as a 78-year-old patient who was recently diagnosed with type 1 diabetes, and a 9-year-old who is learning independence - and managing type 1 diabetes – with the help of the Custom Foods feature. Dr. Miller

brings a practical, person-first approach to care, whether she’s breaking down barriers to technology, helping patients build confidence, or supporting them through the emotional side of diabetes.

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes!

1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%)

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this Beyond the Bolus episode, Mark Heyman, PhD CDCES, shares his experience using the Omnipod 5 App for iPhone as part of the limited market release (LMR). Dr. Heyman discusses this system's new features and how these have benefited his mental well-being and reduced his diabetes distress. Dive in to hear how the Omnipod 5 App for iPhone could help enhance your patient's diabetes management!

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

Recorded Live at ADCES in New Orleans, Louisiana. In this episode, Jennifer Okemah joins us as we dive deep into SmartAdjust™ technology, the groundbreaking algorithm behind the Omnipod 5 Automated Insulin Delivery System. Jennifer breaks down how healthcare providers can fine-tune this innovative tool to better support patients with diabetes, ensuring more personalized insulin delivery to meet your patients’ individual needs. Discover actionable strategies to maximize the benefits of SmartAdjust™ technology, improve patient results, and enhance overall diabetes management.

Whether you’re a seasoned clinician or new to the Omnipod 5, this discussion offers valuable insights to help you get the most out of this cutting-edge technology. Tune in for expert tips and practical guidance!

Recorded Live at ADCES in New Orleans, Louisiana.

Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes.

Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management.

Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes.

------------

Dr. Viral Shah is an endocrinologist. Dr. Shah has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own.

Recorded live at the ADA Conference in Orlando, Florida.

Dive into the future of diabetes management with Eric Benjamin, Insulet’s Chief Product & Customer Experience Officer. In this episode, Eric reveals the innovative journey behind Omnipod, highlighting our relentless focus on customer needs and top-tier performance with every Pod change.

Discover how we're revolutionizing Automated Insulin Delivery with our wearable, tubeless Pod, and learn how these advancements simplify life for people with diabetes. Don't miss this insider's perspective on transforming care through cutting-edge technology.

------------

Eric Benjamin is an employee of Insulet Corporation. The opinions shared in the podcast are his own.

Recorded live at the ADA Conference in Orlando, Florida.

Nancy Hanna is joined by Dr. Pablo Mora who is an Endocrinologist at the North Texas Diabetes & Endocrinology Medical Center in Plano, Texas. During this episode, Nancy and Dr. Mora discuss the integration between the Omnipod 5 Automated Insulin Delivery System and the Dexcom G7 CGM.

Dr. Mora discusses his experience as part of the Limited Market Release for Omnipod 5 with Dexcom G7 and provides insights into the benefit of this integration for his patients with type 1 diabetes.

Listen to learn how Dr. Mora has leveraged this technology to simplify diabetes management with his patients!

------------

Dr. Pablo Mora is an endocrinologist. Dr. Mora has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own.

Recorded live at the ADA Conference in Orlando, Florida 2024.

Nancy Hanna is joined by Cari Berget MPH, RN, CDCES who is a Research Instructor of Pediatric Endocrinology at the University of Colorado School of Medicine – Barbara Davis Center. During this episode, Nancy and Cari discuss automated insulin delivery (AID) candidacy and challenge the perception that people need to meet certain requirements to be considered for AID.

Cari shares her experience prescribing diabetes technology to patients who typically might not been considered for automated insulin delivery and shows the progress and clinical benefits that some of her patients have experienced on Omnipod 5.

------------

Cari Berget, MPH is a Registered Nurse (RN) and a Certified Diabetes Care and Education Specialist (CDCES). Cari Berget has an ongoing commercial relationship with Insulet and Insulet has paid her a fee to participate in this podcast. The opinions and views expressed in this podcast are her own.